期刊
PHARMACEUTICAL RESEARCH
卷 34, 期 7, 页码 1477-1490出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-017-2167-6
关键词
enzyme therapy; gout; hyperuricemia; Lesch-Nyhan disease; polyethylene glycol; purine degradation
资金
- Telethon grant [GGP13149]
Purpose Because of the evolutionary loss of the uricolytic pathway, humans accumulate poorly soluble urate as the final product of purine catabolism. Restoration of uricolysis through enzyme therapy is a promising treatment for severe hyperuricemia caused by deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT). To this end, we studied the effect of PEG conjugation on the activity and stability of the enzymatic complement required for conversion of urate into the more soluble (S)-allantoin. Methods We produced in recombinant form three zebrafish enzymes required in the uricolytic pathway. We carried out a systematic study of the effect of PEGylation on the function and stability of the three enzymes by varying PEG length, chemistry and degree of conjugation. We assayed in vitro the uricolytic activity of the PEGylated enzymatic triad. Results We defined conditions that allow PEGylated enzymes to retain native-like enzymatic activity even after lyophilization or prolonged storage. A combination of the three enzymes in an appropriate ratio allowed efficient conversion of urate to (S)-allantoin with no accumulation of intermediate metabolites. Conclusions Pharmaceutical restoration of the uricolytic pathway is a viable approach for the treatment of severe hyperuricemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据